Table 3 Overall survival in groups without or with adjuvant chemotherapy
From: ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
| Â | No adjuvant chemotherapy group | Adjuvant chemotherapy group | ||||
|---|---|---|---|---|---|---|
| Â | No. (%) | 5-Y OS rate (%) | P | No. (%) | 5-Y OS rate (%) | P |
All patients | 36 (100) | 68.3 | Â | 57 (100) | 52.3 | Â |
ERCC1 status | Â | Â | 0.083 | Â | Â | 0.074 |
Positive | 20 (55.6) | 84.0 | Â | 34 (59.6) | 41.6 | Â |
Negative | 16 (44.4) | 49.2 | Â | 23 (40.4) | 71.8 | Â |
Sex | Â | Â | 0.080 | Â | Â | 0.14 |
Male | 32 (88.9) | 70.6 | Â | 47 (82.5) | 46.2 | Â |
Female | 4 (11.1) | 50.0 | Â | 10 (17.5) | 77.8 | Â |
Age at operation | Â | Â | 0.40 | Â | Â | 0.99 |
≥ 65 years | 24 (66.7) | 70.0 |  | 16 (28.1) | 60.3 |  |
< 65 years | 12 (33.3) | 61.1 | Â | 41 (71.9) | 51.2 | Â |
T stage | Â | Â | 0.21 | Â | Â | 0.57 |
T1-T2 | 15 (41.7) | 83.6 | Â | 4 (7.0) | 50.0 | Â |
T3-T4 | 21 (58.3) | 59.2 | Â | 53 (93.0) | 52.9 | Â |
N stage | Â | Â | 0.10 | Â | Â | 0.73 |
N0 | 32 (88.9) | 70.9 | Â | 29 (50.9) | 47.7 | Â |
N1-3 | 4 (11.1) | 50.0 | Â | 28 (49.1) | 59.1 | Â |
Histologic type | Â | Â | 0.088 | Â | Â | 0.21 |
Squamous differentiation | 2 (5.6) | 50.0 | Â | 9 (15.8) | 77.8 | Â |
Other types | 34 (94.4) | 69.8 | Â | 48 (84.2) | 46.8 | Â |
Pathologic Grade* | Â | Â | 0.35 | Â | Â | 0.47 |
G2 | 3 (8.3) | 100.0 | Â | 7 (12.3) | 71.4 | Â |
G3 | 33 (91.7) | 65.7 | Â | 50 (87.7) | 50.2 | Â |